Skip to main content

Advertisement

SpringerLink
Log in

Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To clarify the impact of comorbidities on treatment strategies and outcomes in patients with rheumatoid arthritis (RA) using a large observational RA cohort, the presence of comorbidities was assessed using the Charlson Comorbidity Index (CCI). Changes in medication, disease activity by Disease Activity Score-28 joint count (DAS28) over 6 months, disability assessed by the Japanese version of the Health Assessment Questionnaire (J-HAQ), and quality of life by EuroQOL-5-Dimensions (EQ-5D) over 1 year in patients with high disease activity (DAS28 > 5.1) at baseline were assessed according to age-adjusted CCI (CCIA) and categorized into four groups (CCIA 0, 1–2, 3–4, and ≥5). Among 5,317 patients, 975 patients (18.3 %) had at least one comorbidity listed by CCI. DAS28, J-HAQ, and EQ-5D increased in severity with increased CCIA levels. Among patients with high disease activity (n = 267), treatment with methotrexate and/or biologics and improved DAS28 scores, shown by attenuated intensity, were associated with increased CCIA levels. J-HAQ improved from 1.29 ± 0.31 to 0.87 ± 0.37 in 1 year in the CCIA 0 group. The adjusted difference (standard error) in J-HAQ at 1 year in CCIA 1–2, 3–4, and ≥5 groups was worse than J-HAQ in the CCIA 0 group by 0.32 (0.09, p < 0.001), 0.45 (0.10, p < 0.001), and 0.45 (0.15, p < 0.01), respectively. The magnitude of improvement of EQ-5D was significantly attenuated with increasing CCIA levels. Thus, patients with comorbidities may not experience the same degree of benefit from recent RA treatments compared with patients without comorbidities in daily practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hyrich K, Symmons D, Watson K, Silman A (2006) Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65:895–898

  2. Michaud K, Wolfe F (2007) Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:885–906

    Article  PubMed  Google Scholar 

  3. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229

    Article  PubMed Central  PubMed  Google Scholar 

  4. Pincus T, Brooks RH, Callahan LF (1994) Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 120:26–34

    Article  CAS  PubMed  Google Scholar 

  5. Sokka T, Abelson B, Pincus T (2008) Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 26:S35–S61

    CAS  PubMed  Google Scholar 

  6. Nakajima A, Inoue E, Tanaka E et al (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39:360–367

    Article  CAS  PubMed  Google Scholar 

  7. Gonzalez A, Maradit Kremers H, Crowson CS et al (2007) The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 56:3583–3587

    Article  PubMed  Google Scholar 

  8. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

    Article  PubMed  Google Scholar 

  9. Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573–586

    Article  PubMed Central  PubMed  Google Scholar 

  10. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639

    Article  CAS  Google Scholar 

  12. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637

    Article  PubMed Central  PubMed  Google Scholar 

  13. Welsing PM, Fransen J, van Riel PL (2005) Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 52:2616–2624

    Article  PubMed  Google Scholar 

  14. Yamanaka H, Inoue E, Singh G et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289

    Article  PubMed  Google Scholar 

  15. Nakajima A, Inoue E, Shidara K et al (2011) Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Mod Rheumatol 21:594–597

    Article  PubMed  Google Scholar 

  16. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  17. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619

    Article  CAS  PubMed  Google Scholar 

  18. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251

    Article  CAS  PubMed  Google Scholar 

  19. Radner H, Smolen JS, Aletaha D (2011) Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 50:381–388

    Article  Google Scholar 

  20. Radner H, Smolen JS, Aletaha D (2010) Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 69:536–541

    Article  PubMed  Google Scholar 

  21. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  PubMed  Google Scholar 

  22. Tanaka E, Hoshi D, Igarashi A et al (2013) Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol 23:742–751

    Article  PubMed  Google Scholar 

  23. Yamanaka H, Seto Y, Tanaka E et al (2013) Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol 23:1–7

    Article  CAS  PubMed  Google Scholar 

  24. Matsuda Y, Singh G, Yamanaka H et al (2003) Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788

    Article  PubMed  Google Scholar 

  25. Prevoo ML, Van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  26. Wolfe F, Caplan L, Michaud K (2007) Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 36:172–178

  27. Lieffers JR, Baracos VE, Winget M, Fassbender K (2011) A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer 117:1957–1965

    Article  PubMed  Google Scholar 

  28. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 56:221–229

    Article  PubMed  Google Scholar 

  29. Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 48:906–910

    Article  Google Scholar 

  30. Iikuni N, Inoue E, Tanaka E et al (2008) Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:519–521

    Article  CAS  Google Scholar 

  31. Seto Y, Inoue E, Shidara K et al (2013) Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study. Mod Rheumatol 23:1179–1185

    Article  CAS  PubMed  Google Scholar 

  32. Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36:8–27

    Article  CAS  PubMed  Google Scholar 

  33. Ranganath VK, Maranian P, Elashoff DA et al (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:1809–1817

    Article  Google Scholar 

Download references

Conflict of interests

Shigeki Momohara speaker fee from Abbvie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Mitsubishi Tanabe, Pfizer, and Takeda; Hisashi Yamanaka speaker fee from Abbvie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Jannsen, Mitsubishi Tanabe, Pfizer and Takeda; All other authors: None.

Author information

Authors and Affiliations

  1. Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo, 162-0054, Japan

    Ayako Nakajima, Eisuke Inoue, Yoko Shimizu, Akiko Kobayashi, Kumi Shidara, Naoki Sugimoto, Yohei Seto, Eiichi Tanaka, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka

Authors
  1. Ayako Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eisuke Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoko Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kumi Shidara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoki Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yohei Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eiichi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Atsuo Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shigeki Momohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hisashi Yamanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayako Nakajima.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakajima, A., Inoue, E., Shimizu, Y. et al. Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clin Rheumatol 34, 441–449 (2015). https://doi.org/10.1007/s10067-014-2750-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2750-8

Keywords

Search

Navigation